Production (Stage)
Celldex Therapeutics, Inc.
CLDX
$20.34
-$0.92-4.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -178.85M | -157.86M | -154.08M | -150.22M | -144.88M |
| Total Depreciation and Amortization | 3.27M | 3.18M | 3.12M | 3.10M | 3.06M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 21.67M | 18.51M | 17.12M | 17.32M | 18.48M |
| Change in Net Operating Assets | -17.60M | -21.60M | -24.00M | 8.30M | 3.98M |
| Cash from Operations | -171.51M | -157.78M | -157.84M | -121.49M | -119.36M |
| Capital Expenditure | -1.84M | -1.92M | -1.83M | -1.44M | -1.58M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 69.87M | -288.21M | -483.51M | -520.01M | -471.99M |
| Cash from Investing | 68.03M | -290.13M | -485.34M | -521.45M | -473.56M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 5.54M | 441.45M | 658.44M | 657.46M | 653.88M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 5.54M | 441.45M | 658.44M | 657.46M | 653.88M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -97.94M | -6.46M | 15.27M | 14.52M | 60.95M |